Sorrentino Domenico

2020–Present: Technologist, Animal Facility and Animal Facility Lab – Preclinical Sector.
Activities focused on animal models for preclinical imaging and behavioral studies, with particular attention to the development of experimental protocols, murine surgery, and technical-scientific support to biomedical research teams.

2016–2020: PhD Student and Marie Skłodowska-Curie Fellow – Université Toulouse III Paul Sabatier / Boston Children’s Hospital.
Project: “Targeting autophagy in ALK-positive cancers.” Focus on the molecular mechanisms and therapeutic implications of autophagy in ALK-positive tumors.

2023: Second-level Master’s Degree in Clinical Research, Medical Affairs & Medical Devices – 24ORE Business School.
In-depth study of clinical trial design, medical affairs, GCP, and artificial intelligence.
Thesis: “Integration of Artificial Intelligence into the Role of the Medical Science Liaison.”

2015–2016: Second-level Master’s Degree in Drug Design and Development – University of Pavia.
Practical training carried out during an ERASMUS Traineeship at DKFZ (German Cancer Research Center), with a focus on preclinical research.

2011–2014: Master’s Degree in Medical Biotechnology – Alma Mater Studiorum University of Bologna.
Experimental thesis: MYCN inhibition and chemotherapy for MYCN-expressing Rhabdomyosarcoma.

2011: Bachelor’s Degree in Biotechnology – Second University of Naples.
Thesis: Use of Agrobacterium tumefaciens for the generation of transgenic plants.

1. "Targeting autophagy in ALK-associated cancers." Cancers (Basel), 2017.
2. "High levels of miR-7-5p potentiate Crizotinib-induced cytokilling and autophagic flux by targeting RAF1 in NPM-ALK positive lymphoma cells." Cancers, 2020.
3. "Combined application of temozolomide and the oncolytic parvovirus H-1 increases cytotoxic effects in cell culture and animal models of pediatric glioblastoma." Neuro-Oncology, 2016.
4. "Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors." J Exp Clin Cancer Res, 2021.
5. "Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth." Cell Death Dis, 2023.

• FELASA-B (ID: 033/11/2015/142) – abilitazione per l’uso di modelli animali (D.Lgs. 26/2014)
• EthoVision XT – analisi del comportamento murino (Noldus)
• IVIS Spectrum– imaging molecolare in vivo (PerkinElmer)
• Vevo F2 LAZR-X20 Photoacoustic Imaging Platform – ecografia ad alta risoluzione e imaging funzionale in vivo (FUJIFILM VisualSonics)
• Newton FT-500 – imaging molecolare in vivo (Vilber)